Mohs 1985.

Methods	Design: Double‐blind randomized placebo controlled crossover study 3‐5 days X 2
Participants	Country: USA Number: 12 patients Sex: 8 males; 4 females. Age: 52‐76 years (mean age: 62.3 years). Diagnosis criteria: Clinical history, CAT scans and laboratory examinations mainly to rule out other possible causes of dementia. Severity of AD: All patients had at least a 1‐year history of cognitive impairment MIT scores 1‐17 (mean, 9.8) DRS 0 ‐5.5 (mean, 2.9)
Interventions	1. placebo 2. oral physostigmine optimal dose (0.5, 1.0, 1.5 or 2.0 mg every 2 hours 8 doses/day)
Outcomes	ADAS
Notes	Preliminary dose finding phase Two patients did not complete the study: one had no improvement on any dose of physostigmine in the dose‐finding phase and the other was dropped out, due to delusions and hallucinations while receiving physostigmine, and excluded from analysis. Oucomes assessed on the last day of each treatment condition.